Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elias Jabbour

Showing results (1-10 of 748) with videos related to

Pageof 75
Sort By:
Oncology (Williston Park, N.Y.)|August 1, 2019
Therapy Options in Treating Acute Lymphoblastic Leukemia in AdultsElias Jabbour
Clinical Advances in Hematology & Oncology : H&O|July 9, 2014
Treating myelodysplastic syndrome when hypomethylating agents stop workingElias Jabbour
Clinical Advances in Hematology & Oncology : H&O|November 7, 2024
Should ponatinib be the standard-of-care tyrosine kinase inhibitor in Ph+ ALL?Elias Jabbour
American Journal of Hematology|January 16, 2016
Chronic myeloid leukemia: First-line drug of choiceElias Jabbour
Clinical Advances in Hematology & Oncology : H&O|March 25, 2010
Imatinib: high dose versus standard doseElias Jabbour
American Journal of Hematology|June 25, 2022
Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoringElias Jabbour, Hagop Kantarjian
Blood|November 21, 2024
Dar-ting at CD38 in T-cell leukemiasJayastu Senapati, Elias Jabbour
Lancet (London, England)|April 16, 2016
Chemoimmunotherapy as a new standard of care for Burkitt leukaemia/lymphomaElias Jabbour, Hagop Kantarjian
Blood Advances|January 4, 2018
Immunotherapy in adult acute lymphoblastic leukemia: the role of monoclonal antibodiesElias Jabbour, Hagop Kantarjian
American Journal of Hematology|April 3, 2020
Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoringElias Jabbour, Hagop Kantarjian
Pageof 75

Showing results (1-10 of 748) with videos related to

Sort By:
Pageof 75
Oncology (Williston Park, N.Y.)|August 1, 2019
Therapy Options in Treating Acute Lymphoblastic Leukemia in AdultsElias Jabbour
Clinical Advances in Hematology & Oncology : H&O|July 9, 2014
Treating myelodysplastic syndrome when hypomethylating agents stop workingElias Jabbour
Clinical Advances in Hematology & Oncology : H&O|November 7, 2024
Should ponatinib be the standard-of-care tyrosine kinase inhibitor in Ph+ ALL?Elias Jabbour
American Journal of Hematology|January 16, 2016
Chronic myeloid leukemia: First-line drug of choiceElias Jabbour
Clinical Advances in Hematology & Oncology : H&O|March 25, 2010
Imatinib: high dose versus standard doseElias Jabbour
American Journal of Hematology|June 25, 2022
Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoringElias Jabbour, Hagop Kantarjian
Blood|November 21, 2024
Dar-ting at CD38 in T-cell leukemiasJayastu Senapati, Elias Jabbour
Lancet (London, England)|April 16, 2016
Chemoimmunotherapy as a new standard of care for Burkitt leukaemia/lymphomaElias Jabbour, Hagop Kantarjian
Blood Advances|January 4, 2018
Immunotherapy in adult acute lymphoblastic leukemia: the role of monoclonal antibodiesElias Jabbour, Hagop Kantarjian
American Journal of Hematology|April 3, 2020
Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoringElias Jabbour, Hagop Kantarjian
Pageof 75